The series A fundraising is the biggest ever for a European biotech firm, according to the data provider PitchBook.

Ozempic, Wegovy or Mounjaro? The battle of the weight-loss injections - As drugs emerge as vital to the Government’s ...

From once-weekly subcutaneously injectable medicines agonizing the glucagon-like peptide 1 receptor (GLP-1R), longer-acting ...

Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...

Newly launched company, Verdiva Bio, is aiming to advance oral and injectable drugs for obesity, with it backed by an ...

The US FDA approved the first generic referencing Victoza, a GLP-1 receptor agonist indicated to improve glycemic control.

As employers grapple with including GLP-1s in their benefits packages, they face a complex decision that boils down to two ...

Recent market research reveals that glucagon-like peptide-1 (GLP-1) injections are set to dominate the obesity treatment ...

A range of GLP-1 weight loss drugs are currently on the market. What are they, what do they do, and where are they available?

Dual- and triple-agonist GLP-1s appear to achieve greater weight loss in an overview of clinical trials of approved and ...

Researchers from Canada reviewed the results of 26 trials to determine which of the weight loss jabs are the most effective ...

The FDA has approved Liraglutide Injection, the first generic version of Victoza, for the treatment of type 2 diabetes.